Phase II Study of Fisetin to Improve Physical Function in Postmenopausal Women After Chemotherapy for Stage I-III Breast Cancer

What this Trial Is About

Researchers are evaluating the effect of fisetin, a natural substance found in strawberries and other foods, on physical function in postmenopausal women who have received chemotherapy for stage I-III breast cancer. This phase II trial focuses on whether fisetin can help improve physical function by eliminating senescent cells that accumulate after chemotherapy, which may cause inflammation and damage to healthy cells. Participants are randomly assigned to receive either fisetin or a placebo orally on days 1, 2, and 3, repeated every two weeks for up to eight weeks, unless disease progression or unacceptable side effects occur. Blood samples are collected throughout the trial to study various biological markers. After treatment, participants are followed yearly for up to three years to monitor long-term outcomes. During the study, participants undergo assessments of physical function such as the 6-minute walk distance, grip strength, and frailty measures. Researchers also evaluate fatigue, neuropathy, cognitive function, quality of life, sleep, anxiety, and depression. Safety and adherence to the study treatment are monitored through patient reports and diaries. The study tracks recurrence-free survival and overall survival over three years, aiming to better understand how fisetin affects health after chemotherapy.

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors